Impact of Solute Carrier Family 47 Member 1 Gene Polymorphism Detection on Therapeutic Effect of Diabetes

Jing Song, Huifang Xu, Wen Zhang, Chunyan Yang, Long Li and Jiajie Luan

Background and Objective: At present, some clinical treatment programs are using the known gene theory to study the relationship between gene polymorphism and drug efficacy and safety with the goal of drug effect and safety. As SLC47A1 (Solute carrier family 47 members 1, SLC47A1) was a transporter for diabetes treatment drug metformin. We conducted a statistical analysis of the SLC47A1 genetic testing results and diabetes patients data in the department of endocrinology in the second quarter of 2019 in our hospital to explore the impact of SLC47A1 gene polymorphism on the treatment of diabetes. Materials and Methods: We investigated 372 cases of SLC47A1 gene test reports and patient medical records, collected information on gender, age, diabetes type, complications and the relationship between genotype and biochemical indicators before and after metformin treatment and perform statistical analysis on it. Results: GG genotype had the highest incidence in men, <30 years or type 2 diabetes patients, GA genotypes had the highest incidence in men, >30 years or type 2 diabetes patients and AA genotype had the highest incidence in men, <30 years or type 1 diabetes. Besides, the complications that each genotype tended to occur were also significantly different. At the same time, compared with the biochemical parameters before the guidance, the biochemical parameters after the guidance were significantly improved. Conclusion: The guidance of SLC47A1 gene polymorphism on metformin medication could improve diabetes treatment effect and patients with AA genotype had the best treatment effect.

View Fulltext Back